Trial Profile

Comparison of the efficacies of tofacitinib and abatacept in patients with rheumatoid arthritis by propensity score matching and their clinical significance

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 05 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abatacept (Primary) ; Abatacept (Primary) ; Tofacitinib (Primary)
Indications Rheumatoid arthritis
Focus Therapeutic Use
Acronyms TOF-ABT study

Most Recent Events

31 Aug 2021 Primary endpoint has not been met (Comparison of DAS28-ESR remission rates between tofacitinib (TOF) and abatacept (ABT) at 6 months after initiation of treatment) , according to Results published in the Arthritis Research and Therapy
31 Aug 2021 Results published in the Arthritis Research and Therapy
19 Jul 2021 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com